Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of the PPARγ.
Lead Product(s): NAC-GED-0507
Therapeutic Area: Dermatology Product Name: NAC-GED-0507
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Torii Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2023